<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD00680000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q92731</UniProt_ID>
  <Seq_Length>530</Seq_Length>
  <Molecule_Weight>59216</Molecule_Weight>
  <KEGG_ID>hsa:2100</KEGG_ID>
  <Orthology_ID>K08551</Orthology_ID>
  <EBI_ID>EBI-78505</EBI_ID>
  <Function_Summary>Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner. Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by ESR1 and ESR2 is rapidly lost at 37 degrees Celsius in the absence of ligand while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen loss in DNA-binding at elevated temperature is more gradual.</Function_Summary>
  <Pfam_ID>PF12497:ERbeta_N@@PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>1</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>3</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Nuclear receptor subfamily 3 group A member 2</Alias>
      <Alias>ER-beta</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a lipid.</Detail>
      <Keyword>Lipid binding</Keyword>
      <Ontology_ID>GO:0008289</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the estrogen response element (ERE), a conserved sequence found in the promoters of genes whose expression is regulated in response to estrogen.</Detail>
      <Keyword>Estrogen response element binding</Keyword>
      <Ontology_ID>GO:0034056</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>A ligand-dependent receptor found in the nucleus of the cell.</Detail>
      <Keyword>Ligand-dependent nuclear receptor activity</Keyword>
      <Ontology_ID>GO:0004879</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a activating transcription factor and also with the basal transcription machinery in order to increase the frequency, rate or extent of transcription. Cofactors generally do not bind DNA, but rather mediate protein-protein interactions between activating transcription factors and the basal transcription machinery.</Detail>
      <Keyword>Transcription coactivator activity</Keyword>
      <Ontology_ID>GO:0003713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a steroid, any of a large group of substances that have in common a ring system based on 1,2-cyclopentanoperhydrophenanthrene.</Detail>
      <Keyword>Steroid binding</Keyword>
      <Ontology_ID>GO:0005496</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any enzyme.</Detail>
      <Keyword>Enzyme binding</Keyword>
      <Ontology_ID>GO:0019899</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a sequence of DNA that is part of a core promoter region composed of the transcription start site and binding sites for the basal transcription machinery. The transcribed region might be described as a gene, cistron, or operon.</Detail>
      <Keyword>Core promoter sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0001046</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with estrogen to initiate a change in cell activity.</Detail>
      <Keyword>Estrogen receptor activity</Keyword>
      <Ontology_ID>GO:0030284</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacts with receptors to reduce the action of another ligand, the agonist.</Detail>
      <Keyword>Receptor antagonist activity</Keyword>
      <Ontology_ID>GO:0048019</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process in which a ligand-bound hormone receptor acts in the nucleus to modulate the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Regulation of transcription from RNA polymerase II promoter by nuclear hormone receptor</Keyword>
      <Ontology_ID>GO:0034339</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of an estrogen binding to its receptor.</Detail>
      <Keyword>Estrogen receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0030520</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that mediates the transfer of information from one cell to another.</Detail>
      <Keyword>Cell-cell signaling</Keyword>
      <Ontology_ID>GO:0007267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of activity of a transcription factor, any factor involved in the initiation or regulation of transcription.</Detail>
      <Keyword>Positive regulation of transcription factor activity</Keyword>
      <Ontology_ID>GO:0051091</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell growth.</Detail>
      <Keyword>Negative regulation of cell growth</Keyword>
      <Ontology_ID>GO:0030308</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>87</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>488</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHHEYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAEPQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHYGVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMMGLMWRSIDHPGKLIFAPDLVLDRDEGKCVEGILEIFDMLLATTSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVTDALVWVIAKSGISSQQQSMRLANLLMLLSHVRHASNKGMEHLLNMKCKNVVPVYDLLLEMLNAHVLRGCKSSITGSECSPAEDSKSKEGSQNPQSQ</Protein_Seq>
    <DNA_Seq>GTTGACAGCCATTATACTTGCCCACGAATCTTTGAGAACATTATAATGACCTTTGTGCCTCTTCTTGCAAGGTGTTTTCTCAGCTGTTATCTCAAGACATGGATATAAAAAACTCACCATCTAGCCTTAATTCTCCTTCCTCCTACAACTGCAGTCAATCCATCTTACCCCTGGAGCACGGCTCCATATACATACCTTCCTCCTATGTAGACAGCCACCATGAATATCCAGCCATGACATTCTATAGCCCTGCTGTGATGAATTACAGCATTCCCAGCAATGTCACTAACTTGGAAGGTGGGCCTGGTCGGCAGACCACAAGCCCAAATGTGTTGTGGCCAACACCTGGGCACCTTTCTCCTTTAGTGGTCCATCGCCAGTTATCACATCTGTATGCGGAACCTCAAAAGAGTCCCTGGTGTGAAGCAAGATCGCTAGAACACACCTTACCTGTAAACAGAGAGACACTGAAAAGGAAGGTTAGTGGGAACCGTTGCGCCAGCCCTGTTACTGGTCCAGGTTCAAAGAGGGATGCTCACTTCTGCGCTGTCTGCAGCGATTACGCATCGGGATATCACTATGGAGTCTGGTCGTGTGAAGGATGTAAGGCCTTTTTTAAAAGAAGCATTCAAGGACATAATGATTATATTTGTCCAGCTACAAATCAGTGTACAATCGATAAAAACCGGCGCAAGAGCTGCCAGGCCTGCCGACTTCGGAAGTGTTACGAAGTGGGAATGGTGAAGTGTGGCTCCCGGAGAGAGAGATGTGGGTACCGCCTTGTGCGGAGACAGAGAAGTGCCGACGAGCAGCTGCACTGTGCCGGCAAGGCCAAGAGAAGTGGCGGCCACGCGCCCCGAGTGCGGGAGCTGCTGCTGGACGCCCTGAGCCCCGAGCAGCTAGTGCTCACCCTCCTGGAGGCTGAGCCGCCCCATGTGCTGATCAGCCGCCCCAGTGCGCCCTTCACCGAGGCCTCCATGATGATGTCCCTGACCAAGTTGGCCGACAAGGAGTTGGTACACATGATCAGCTGGGCCAAGAAGATTCCCGGCTTTGTGGAGCTCAGCCTGTTCGACCAAGTGCGGCTCTTGGAGAGCTGTTGGATGGAGGTGTTAATGATGGGGCTGATGTGGCGCTCAATTGACCACCCCGGCAAGCTCATCTTTGCTCCAGATCTTGTTCTGGACAGGGATGAGGGGAAATGCGTAGAAGGAATTCTGGAAATCTTTGACATGCTCCTGGCAACTACTTCAAGGTTTCGAGAGTTAAAACTCCAACACAAAGAATATCTCTGTGTCAAGGCCATGATCCTGCTCAATTCCAGTATGTACCCTCTGGTCACAGCGACCCAGGATGCTGACAGCAGCCGGAAGCTGGCTCACTTGCTGAACGCCGTGACCGATGCTTTGGTTTGGGTGATTGCCAAGAGCGGCATCTCCTCCCAGCAGCAATCCATGCGCCTGGCTAACCTCCTGATGCTCCTGTCCCACGTCAGGCATGCGAGTAACAAGGGCATGGAACATCTGCTCAACATGAAGTGCAAAAATGTGGTCCCAGTGTATGACCTGCTGCTGGAGATGCTGAATGCCCACGTGCTTCGCGGGTGCAAGTCCTCCATCACGGGGTCCGAGTGCAGCCCGGCAGAGGACAGTAAAAGCAAAGAGGGCTCCCAGAACCCACAGTCTCAGTGACGCCTGGCCCTGAGGTGAACTGGCCCACAGAGGTCACAAGCTGAAGCGT</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Thymus</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Placenta</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Testis</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Spleen</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Ovary</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ESR2</Gene_Name>
    <Gene_Alias>ESTRB; NR3A2</Gene_Alias>
    <Gene_ID>2100</Gene_ID>
    <Genbank_ACCN>NM_001040275</Genbank_ACCN>
    <Protein_ACCN>NP_001035365</Protein_ACCN>
    <HGNC_ID>3468</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2100</Gene_URL>
    <UCSC_ID>uc010aqc.1</UCSC_ID>
    <EMBL_ID>ENSG00000140009</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P53041</Uniprot_ID>
      <Gene_Name>PPP5C</Gene_Name>
      <EBI_ID>EBI-716663</EBI_ID>
      <PPI_EBI_URL>EBI-78505,EBI-716663</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Primary Pigmented Nodular Adrenocortical Disease</Disease_Name>
      <Disease_Detail>Primary Pigmented Nodular Adrenocortical Disease</Disease_Detail>
      <Disease_DB>PRM051</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/primary_pigmented_nodular_adrenocortical_disease?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometriosis</Disease_Name>
      <Disease_Detail>Endometriosis</Disease_Detail>
      <Disease_DB>END044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometriosis?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Germ Cell Cancer</Disease_Name>
      <Disease_Detail>Germ Cell Cancer</Disease_Detail>
      <Disease_DB>GRM005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/germ_cell_cancer?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lobular Neoplasia</Disease_Name>
      <Disease_Detail>Lobular Neoplasia</Disease_Detail>
      <Disease_DB>LBL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lobular_neoplasia?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Progesterone Resistance</Disease_Name>
      <Disease_Detail>Progesterone Resistance</Disease_Detail>
      <Disease_DB>PRG014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/progesterone_resistance?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Enchondroma</Disease_Name>
      <Disease_Detail>Enchondroma</Disease_Detail>
      <Disease_DB>ENC014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/enchondroma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometrial Carcinoma</Disease_Name>
      <Disease_Detail>Endometrial Cancer</Disease_Detail>
      <Disease_DB>END042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometrial_carcinoma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gender Identity Disorder</Disease_Name>
      <Disease_Detail>Gender Identity Disorder</Disease_Detail>
      <Disease_DB>GND002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gender_identity_disorder?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteoporosis</Disease_Name>
      <Disease_Detail>Osteoporosis</Disease_Detail>
      <Disease_DB>OST002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteoporosis?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dental Fluorosis</Disease_Name>
      <Disease_Detail>Dental Fluorosis</Disease_Detail>
      <Disease_DB>DNT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dental_fluorosis?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cystadenocarcinoma</Disease_Name>
      <Disease_Detail>Cystadenoma</Disease_Detail>
      <Disease_DB>CYS014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cystadenocarcinoma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Clear Cell Adenocarcinoma</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR034</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_clear_cell_adenocarcinoma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vaginitis</Disease_Name>
      <Disease_Detail>Vaginitis</Disease_Detail>
      <Disease_DB>VGN023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vaginitis?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Peritoneal Mesothelioma</Disease_Name>
      <Disease_Detail>Peritoneal Mesothelioma</Disease_Detail>
      <Disease_DB>PRT096</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/peritoneal_mesothelioma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Malignant Peritoneal Mesothelioma</Disease_Name>
      <Disease_Detail>Malignant Peritoneal Mesothelioma</Disease_Detail>
      <Disease_DB>MLG002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/malignant_peritoneal_mesothelioma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Serous Cystadenocarcinoma</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_serous_cystadenocarcinoma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Transsexualism</Disease_Name>
      <Disease_Detail>Transsexualism</Disease_Detail>
      <Disease_DB>TRN007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transsexualism?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Serous Cystadenocarcinoma</Disease_Name>
      <Disease_Detail>Serous Cystadenocarcinoma</Disease_Detail>
      <Disease_DB>SRS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/serous_cystadenocarcinoma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leiomyoma</Disease_Name>
      <Disease_Detail>Leiomyoma</Disease_Detail>
      <Disease_DB>LMY002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leiomyoma?search=ESR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fallopian Tube Cancer</Disease_Name>
      <Disease_Detail>Fallopian Tube Cancer</Disease_Detail>
      <Disease_DB>FLL026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fallopian_tube_cancer?search=ESR2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal Structure of Estrogen Receptor beta complexed with WAY-797</PDB_Title>
      <PDB_ID>1U3S</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U3S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.</PubMed_Title>
      <Author>Malamas MS, et al.</Author>
      <Journal>J Med Chem. 2004 Oct 7;47(21):5021-40.</Journal>
      <PubMed_ID>15456246</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of estrogen receptor beta complexed with 3-Bromo-6-hydroxy-2-(4-hydroxy-phenyl)-inden-1-one</PDB_Title>
      <PDB_ID>1ZAF</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZAF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones.</PubMed_Title>
      <Author>McDevitt RE, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2005 Jun 15;15(12):3137-42.</Journal>
      <PubMed_ID>15876535</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-397</PDB_Title>
      <PDB_ID>1U9E</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U9E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of estrogen receptor-beta selective ligands.</PubMed_Title>
      <Author>Manas ES, et al.</Author>
      <Journal>J Am Chem Soc. 2004 Nov 24;126(46):15106-19.</Journal>
      <PubMed_ID>15548008</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST GENISTEIN</PDB_Title>
      <PDB_ID>1QKM</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QKM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist.</PubMed_Title>
      <Author>Pike AC, et al.</Author>
      <Journal>EMBO J. 1999 Sep 1;18(17):4608-18.</Journal>
      <PubMed_ID>10469641</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Benzopyrans are Selective Estrogen Receptor beta Agonists (SERBAs) with Novel Activity in Models of Benign Prostatic Hyperplasia</PDB_Title>
      <PDB_ID>2I0G</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2I0G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.</PubMed_Title>
      <Author>Norman BH, et al.</Author>
      <Journal>J Med Chem. 2006 Oct 19;49(21):6155-7.</Journal>
      <PubMed_ID>17034120</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of estrogen receptor beta complexed with way-202196</PDB_Title>
      <PDB_ID>1YYE</PDB_ID>
      <Resolution>2.03</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YYE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.</PubMed_Title>
      <Author>Mewshaw RE, et al.</Author>
      <Journal>J Med Chem. 2005 Jun 16;48(12):3953-79.</Journal>
      <PubMed_ID>15943471</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Estrogen receptor beta ligand-binding domain complexed to a benzopyran ligand</PDB_Title>
      <PDB_ID>2QTU</PDB_ID>
      <Resolution>2.53</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QTU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies.</PubMed_Title>
      <Author>Richardson TI, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2007 Oct 15;17(20):5563-6.</Journal>
      <PubMed_ID>17804226</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Estrogen Receptor beta complexed with CL-272</PDB_Title>
      <PDB_ID>1U3Q</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U3Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.</PubMed_Title>
      <Author>Malamas MS, et al.</Author>
      <Journal>J Med Chem. 2004 Oct 7;47(21):5021-40.</Journal>
      <PubMed_ID>15456246</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R,R)-5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol</PDB_Title>
      <PDB_ID>1L2J</PDB_ID>
      <Resolution>2.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1L2J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism.</PubMed_Title>
      <Author>Shiau AK, et al.</Author>
      <Journal>Nat Struct Biol. 2002 May;9(5):359-64.</Journal>
      <PubMed_ID>11953755</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-244</PDB_Title>
      <PDB_ID>1X78</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1X78</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of estrogen receptor-beta selective ligands.</PubMed_Title>
      <Author>Manas ES, et al.</Author>
      <Journal>J Am Chem Soc. 2004 Nov 24;126(46):15106-19.</Journal>
      <PubMed_ID>15548008</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Estrogen receptor beta ligand-binding domain complexed to a benzopyran ligand</PDB_Title>
      <PDB_ID>2Z4B</PDB_ID>
      <Resolution>2.34</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Z4B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification.</PubMed_Title>
      <Author>Richardson TI, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2007 Sep 1;17(17):4824-8.</Journal>
      <PubMed_ID>17614275</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Estrogen Receptor Beta Complexed with WAY-555</PDB_Title>
      <PDB_ID>2NV7</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2NV7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives.</PubMed_Title>
      <Author>Mewshaw RE, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2007 Feb 15;17(4):902-6.</Journal>
      <PubMed_ID>17188490</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of estrogen receptor beta complexed with 1-chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol</PDB_Title>
      <PDB_ID>1YY4</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YY4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.</PubMed_Title>
      <Author>Mewshaw RE, et al.</Author>
      <Journal>J Med Chem. 2005 Jun 16;48(12):3953-79.</Journal>
      <PubMed_ID>15943471</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta</PDB_Title>
      <PDB_ID>2FSZ</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FSZ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00680003</ASD_Ligand>
      <PubMed_Title>A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta.</PubMed_Title>
      <Author>Wang Y, et al.</Author>
      <Journal>Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9908-11.</Journal>
      <PubMed_ID>16782818</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST</PDB_Title>
      <PDB_ID>2JJ3</PDB_ID>
      <Resolution>2.28</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JJ3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring.</PubMed_Title>
      <Author>Norman BH, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2007 Sep 15;17(18):5082-5.</Journal>
      <PubMed_ID>17662603</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human estrogen receptor beta ligand-binding domain in complex with compound 45</PDB_Title>
      <PDB_ID>2GIU</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2GIU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands.</PubMed_Title>
      <Author>Wilkening RR, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2006 Jul 1;16(13):3489-94.</Journal>
      <PubMed_ID>16632357</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH GENISTEIN</PDB_Title>
      <PDB_ID>1X7J</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1X7J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods.</PubMed_Title>
      <Author>Manas ES, et al.</Author>
      <Journal>Structure. 2004 Dec;12(12):2197-207.</Journal>
      <PubMed_ID>15576033</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Estrogen Receptor beta with Selective Triazine Modulator</PDB_Title>
      <PDB_ID>1NDE</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NDE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.</PubMed_Title>
      <Author>Henke BR, et al.</Author>
      <Journal>J Med Chem. 2002 Dec 5;45(25):5492-505.</Journal>
      <PubMed_ID>12459017</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697</PDB_Title>
      <PDB_ID>1X76</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1X76</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of estrogen receptor-beta selective ligands.</PubMed_Title>
      <Author>Manas ES, et al.</Author>
      <Journal>J Am Chem Soc. 2004 Nov 24;126(46):15106-19.</Journal>
      <PubMed_ID>15548008</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Estrogen Receptor beta complexed with WAY-338</PDB_Title>
      <PDB_ID>1U3R</PDB_ID>
      <Resolution>2.21</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U3R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.</PubMed_Title>
      <Author>Malamas MS, et al.</Author>
      <Journal>J Med Chem. 2004 Oct 7;47(21):5021-40.</Journal>
      <PubMed_ID>15456246</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH ERB-041</PDB_Title>
      <PDB_ID>1X7B</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1X7B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of estrogen receptor-beta selective ligands.</PubMed_Title>
      <Author>Manas ES, et al.</Author>
      <Journal>J Am Chem Soc. 2004 Nov 24;126(46):15106-19.</Journal>
      <PubMed_ID>15548008</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ERa LBD in complex with RU100132</PDB_Title>
      <PDB_ID>4DMA</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DMA</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00688001</ASD_Ligand>
      <PubMed_Title>Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors.</PubMed_Title>
      <Author>Osz, J., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2012)109:E588-E594</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22355136?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.bb.html</SCOP_URL>
    <CATH_Class>Mainly alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1u3q</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Reference>Nettles K W, et al. Mol Cell. 2004,13(3):317-327.</Site_Reference>
      <PubMed_ID>14967140</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00680001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00680002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00680003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00688001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>